Clinical and cost–effectiveness of insulin degludec: from clinical trials to clinical practice. (May 2015)

• Record Type: Journal Article
• Authors: Evans, Marc; McEwan, Phil
• Is Part Of: Journal of comparative effectiveness research. Volume 4:Number 3(2015)
• Page Start: 279
• Page End: 286
• Publication Date: 2015-05
• Subjects: analog -- cost–effectiveness -- diabetes -- flexible dosing -- hypoglycemia -- insulin degludec -- real-world studies; Medical care -- Research -- Periodicals; Medical care -- Research -- Evaluation -- Periodicals; Medical care -- Decision making -- Periodicals; Evidence-based medicine -- Periodicals; Medicine, Comparative -- Periodicals; 362.1072
• DOI: 10.2217/cer.15.10
• Languages: English
• ISSNs: 2042-6305

Abstract

The increasing prevalence of diabetes presents one of the greatest challenges to healthcare provision in modern times, with the cost of treating diabetes and its related complications representing a significant proportion of healthcare expenditure. In recent years, many new therapeutic entities have been developed with the aim of improving glycemic control, and thus slowing the development of micro- and macrovascular complications. Insulin degludec is a new-generation basal insulin analog with an ultra-long duration of action and low day-to-day and hour-to-hour intrapatient variability in blood glucose-lowering action. In this review, we consider evidence from clinical trials and real-world studies demonstrating the clinical benefits and cost–effectiveness of insulin degludec and its potential for improving patient care.